產品詳情
簡單介紹：
重組人上皮調節蛋白蛋白與其它公司提供的重組蛋白不同，rHuEpiregulin蛋白產品為采用CFS的無細胞麥胚蛋白合成系統表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人上皮調節蛋白蛋白（全長序列）產品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人上皮調節蛋白蛋白
| Synonyms | EREG |
| Species | Human |
| Accession | O14944 |
| GeneID | 2069 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人上皮調節蛋白蛋白Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 49 amino acids. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | VAQVSITKCS SDMNGYCLHG QCIYLVDMSQ NYCRCEVGYT GVRCEHFFL |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人上皮調節蛋白蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuEpiregulin as determined by LAL method. |
| Reconstitution | 重組人上皮調節蛋白蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人上皮調節蛋白蛋白 | |
| Reference |
1. Xi QS, Qian XG, Zhou QW, et al. 2000. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 32: 295-8. 2. Kuntz E, Broca C, Komurasaki T, et al. 2005. Growth Factors, 23: 285-93. 3. Shirakata Y, Kishimoto J, Tokumaru S, et al. 2007. J Dermatol Sci, 45: 69-72. 4. Thuong NT, Hawn TR, Chau TT, et al. 2012. Genes Immun, 13: 275-81. |
| Background | Epiregulin encoded by the EREG gene in humans, is a member of the EGF family of growth factors. This family also includes epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, amphiregulin (ARG), HB (heparin-binding)-EGF, betacellulin, and the various heregulins. Epiregulin is expressed mainly in the placenta and peripheral blood leukocytes and in certain carcinomas of the bladder, lung, kidney and colon. It stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and vascular smooth muscle cells. Additionally, it inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence. |
